Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 6Withdrawn 1Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 6Neoplasm Metastasis 4Colonic Neoplasms 4Rectal Neoplasms 3Stomach Neoplasms 2Peritoneal Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Gallbladder Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Disease Progression 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 100130-nm albumin-bound paclitaxel 34Oxaliplatin 28Capecitabine 27Fluorouracil 25Albumin-Bound Paclitaxel 23Leucovorin 19Irinotecan 18Erlotinib Hydrochloride 14Cyclophosphamide 12Radiosurgery 11pembrolizumab 10Radiotherapy 10Nivolumab 10Bevacizumab 10Surgical Procedures, Operative 9avelumab 7Docetaxel 7Taxes 6Cisplatin 6ruxolitinib 5folfirinox 5Specimen Handling 5Paclitaxel 5Everolimus 5Cetuximab 5ALT-803 5trametinib 4spartalizumab 4fludarabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Pancreatic Neoplasms × Folfox protocol × Clear all
NCT01632306 2019-01-15

A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer

Eli Lilly and Company

Phase 1/2 Terminated
13 enrolled 12 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡